you won't find a better service for investors, these guys uncover the undervalued and overlooked companies across the markets and deliver high quality reports detailing info about the company and industry that investors love
Do you think he made a good impression? Down another couple percent today on 14K of shares, 14K at 2.60: that is about how much Berlin earns in about 2 weeks. Sometimes, well all the time, I wish he'd save the travel expenses.
Can you imagine the embarrassing investor questions? How have the buyers of your last secondary fared? Are you showing a gross profit on sales? How long do you think it will take before gross profits pay your salary?
Maybe it is a presentation only; no follow-up questions.
Before you make any decision about ROSG be sure to read the new eBook from ExplosiveOTC, an incredible resource that details critical information about the markets. Simply enter the promo code ROSG when signing up for their incredible alerts.
is that the place to announce news? This is his usual blah blah $600MM market 300K people unmet demand BS story to meet people from the industry and justify his $1m salary. Meanwhile the stupid stock has resumed its' traditional pattern - slight pump at the open and a slide lower highs lower lows. More like mutilated remnants of the shareholders trying to sell 20K into the tax loss December ..IMHO
point is - Berlin would never provide any guidance and sales projections, he would never brake down the sale source, would never indicate what is that they expect from the new tests and how soon. So a secondary is a looming proposal and it is more and more spooky with the rise of the staff and the money draining new and numerous studies.
Sadly true, and that resistance can be overcome with the right management decisions, or as you write, with a partnership that has the respect and reputation we do not.
Yes, sell or partner up with a sizable entity, or drag along hoping for a miracle that somehow sales will pick up to stop bleeding but facing imminent dilution in case you spread yourself thin and they have rather short time left and they won't risk waiting till the last hurdle is overcome as those may be plenty. As we learned hard way the Medicare coverage is not a free ticket to jettison the sales at all. There is a severe medical community resistance they are struggling to overcome.
Your reasons can be interpreted either way -- sell the company or hold it until more data is available. The company you describe sounds like a micro cap company still in its incubation period. That means investors understand the timeline stretches into the future, and one cannot make decisions about the company's potential based on quarter by quarter results. Year over year results will provide a better picture of the company's prognosis. Or, at least from your dates, the middle of next year could bring some news that interests Wall Street again.
We all know the problems that have occurred in the past two years, especially with top management, and we have also seen how the stock price can spike higher when some news (Medicare approval of CUP test) does interest money managers. I have no idea whether or not such interest will return, but if as you have written, there are several news items to be released next year that might reignite the fire, I would rather wait and see. We are still in the tax loss selling period, and the frustration is more pronounced when we can see no reason to buy. Talking about selling at this point, however, might not be in the interest of long-term shareholders who are waiting for a real turnaround in sales and product development.
What is the burn rate versus the current and projected FCF in the near term? The pipe line to be counted on is the thyroid gland test to some time in mid 2015 that, lungs and kidney test are in need of Medicare coverage all scheduled to be obtained in the mid of 2015 as well. There is some unknown (size wise) revenue expected this month from Florida and lab sharing, but wouldn't move a needle on the grander scale. In general the prior announced collaborations with the health service providers with the alleged broad pool of potential customers have not resulted in sales jump. They have 12 man strong regional sale force that along with the collaborator have managed to sell on average 1 (one) test per week per salesmen which is ridiculous. So in order to utilize their IP and ambitious new studies they need war chest of long term funds ... So no, if this technology is of value to larger entity they would be stupid to not seek a fat partner. Question is - is that iP of such real value, where are the buyers as there is a multitude of medical test companies struggling to survive without Medicare coverage. Is Berlin determined to self serve and dilute or he finally wakes up to common good?
Why sell? Have you seen the latest sales data? Are sales increasing or decreasing? Are we making new alliances, like the Moffitt Cancer Center one, or not? Are there no new products in the pipeline?
Please make a reasonable case based on sales and products for selling. TIA.
Berlin knows that he will not be able to raise anymore funds at this current volume. ROSG has to be sold and they need to start thinking rationally. They cannot do it on their own and calls need to be made now! He has got his shares now they have to make some news to get the price up and show valuation to a buyer or this thing is sunk!